UK markets closed

Celldex Therapeutics, Inc. (CLDX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
32.02+1.81 (+5.99%)
At close: 04:00PM EST
32.50 +0.48 (+1.50%)
After hours: 04:33PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 1.75B
Enterprise value 1.52B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)346.90
Price/book (mrq)7.11
Enterprise value/revenue 348.54
Enterprise value/EBITDA -11.54

Trading information

Stock price history

Beta (5Y monthly) 2.06
52-week change 3-12.66%
S&P500 52-week change 314.90%
52-week high 348.40
52-week low 322.11
50-day moving average 326.67
200-day moving average 332.58

Share statistics

Avg vol (3-month) 3728k
Avg vol (10-day) 3785.1k
Shares outstanding 554.69M
Implied shares outstanding 654.69M
Float 841.02M
% held by insiders 10.31%
% held by institutions 1108.75%
Shares short (14 Nov 2023) 47.88M
Short ratio (14 Nov 2023) 47.38
Short % of float (14 Nov 2023) 417.02%
Short % of shares outstanding (14 Nov 2023) 414.41%
Shares short (prior month 12 Oct 2023) 45.57M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 310 Feb 2019
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 310 Feb 2019

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Sept 2023


Profit margin 0.00%
Operating margin (ttm)-2,718.46%

Management effectiveness

Return on assets (ttm)-25.94%
Return on equity (ttm)-42.09%

Income statement

Revenue (ttm)4.37M
Revenue per share (ttm)0.09
Quarterly revenue growth (yoy)272.70%
Gross profit (ttm)-79.9M
EBITDA -131.88M
Net income avi to common (ttm)-124.61M
Diluted EPS (ttm)-2.65
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)235.35M
Total cash per share (mrq)4.98
Total debt (mrq)2.85M
Total debt/equity (mrq)1.15%
Current ratio (mrq)8.84
Book value per share (mrq)5.22

Cash flow statement

Operating cash flow (ttm)-96.52M
Levered free cash flow (ttm)-49.55M